ScienceGate
Advanced Search
Author Search
Journal Finder
Blog
Sign in / Sign up
ScienceGate
Search
Author Search
Journal Finder
Blog
Sign in / Sign up
Nonacog beta pegol in previously treated children with hemophilia B: results from an international open-label phase 3 trial
Journal of Thrombosis and Haemostasis
◽
10.1111/jth.13360
◽
2016
◽
Vol 14
(8)
◽
pp. 1521-1529
◽
Cited By ~ 26
Author(s):
M. Carcao
◽
M. Zak
◽
F. Abdul Karim
◽
H. Hanabusa
◽
S. Kearney
◽
...
Keyword(s):
Hemophilia B
◽
Open Label
◽
Phase 3
◽
Open Label Phase
◽
Previously Treated
Download Full-text
Related Documents
Cited By
References
Faculty Opinions recommendation of Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial.
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature
◽
10.3410/f.732365471.793564969
◽
2019
◽
Author(s):
Anna Rita Migliaccio
Keyword(s):
Open Label
◽
Phase 3
◽
Open Label Phase
◽
Previously Treated
Download Full-text
Abstract CT041: ORIENT-3: A randomized, open-label, phase 3 study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small-cell lung cancer (sqNSCLC)
10.1158/1538-7445.am2021-ct041
◽
2021
◽
Author(s):
Yuankai Shi
◽
Lin Wu
◽
Xinmin Yu
◽
Yan Wang
◽
Puyuan Xing
◽
...
Keyword(s):
Lung Cancer
◽
Small Cell Lung Cancer
◽
Cell Lung Cancer
◽
Small Cell
◽
Small Cell Lung
◽
Open Label
◽
Phase 3
◽
Open Label Phase
◽
Previously Treated
Download Full-text
Poster: CML-353: Health Care Resource Utilization (HCRU) with Asciminib and Bosutinib among Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs): Results from the Multicenter, Open-Label Phase 3 ASCEMBL Trial
Clinical Lymphoma Myeloma & Leukemia
◽
10.1016/s2152-2650(21)01411-7
◽
2021
◽
Vol 21
◽
pp. S224
Author(s):
B Douglas Smith
◽
Jorge E Cortes
◽
Delphine Rea
◽
Michael J Mauro
◽
Pallavi Patwardhan
◽
...
Keyword(s):
Health Care
◽
Myeloid Leukemia
◽
Kinase Inhibitors
◽
Chronic Phase
◽
Health Care Resource
◽
Open Label
◽
Phase 3
◽
Health Care Resource Utilization
◽
Open Label Phase
◽
Previously Treated
Download Full-text
Nivolumab versus docetaxel in a predominantly Chinese patient population with previously treated advanced non-small cell lung cancer: 2-year follow-up from a randomized, open-label, phase 3 study (CheckMate 078)
Lung Cancer
◽
10.1016/j.lungcan.2020.11.013
◽
2021
◽
Vol 152
◽
pp. 7-14
Author(s):
Shun Lu
◽
Jie Wang
◽
Ying Cheng
◽
Tony Mok
◽
Jianhua Chang
◽
...
Keyword(s):
Lung Cancer
◽
Patient Population
◽
Chinese Patient
◽
Small Cell
◽
Small Cell Lung
◽
Open Label
◽
Phase 3
◽
Open Label Phase
◽
Previously Treated
Download Full-text
Pembrolizumab versus paclitaxel for previously treated advanced gastric or gastroesophageal junction cancer (KEYNOTE‐063): A randomized, open‐label, phase 3 trial in Asian patients
Cancer
◽
10.1002/cncr.34019
◽
2021
◽
Author(s):
Hyun Cheol Chung
◽
Yoon‐Koo Kang
◽
Zhendong Chen
◽
Yuxian Bai
◽
Wan Zamaniah Wan Ishak
◽
...
Keyword(s):
Gastroesophageal Junction
◽
Open Label
◽
Phase 3
◽
Asian Patients
◽
Gastroesophageal Junction Cancer
◽
Open Label Phase
◽
Previously Treated
Download Full-text
Momelotinib versus best available therapy in patients with myelofibrosis previously treated with ruxolitinib (SIMPLIFY 2): a randomised, open-label, phase 3 trial
The Lancet Haematology
◽
10.1016/s2352-3026(17)30237-5
◽
2018
◽
Vol 5
(2)
◽
pp. e73-e81
◽
Cited By ~ 57
Author(s):
Claire N Harrison
◽
Alessandro M Vannucchi
◽
Uwe Platzbecker
◽
Francisco Cervantes
◽
Vikas Gupta
◽
...
Keyword(s):
Open Label
◽
Phase 3
◽
Open Label Phase
◽
Previously Treated
Download Full-text
CML-353: Health Care Resource Utilization (HCRU) with Asciminib and Bosutinib among Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Previously Treated with ≥2 Tyrosine Kinase Inhibitors (TKIs): Results from the Multicenter, Open-Label Phase 3 ASCEMBL Trial
Clinical Lymphoma Myeloma & Leukemia
◽
10.1016/s2152-2650(21)01781-x
◽
2021
◽
Vol 21
◽
pp. S334
Author(s):
B Douglas Smith
◽
Jorge E Cortes
◽
Delphine Rea
◽
Michael J Mauro
◽
Pallavi Patwardhan
◽
...
Keyword(s):
Health Care
◽
Myeloid Leukemia
◽
Kinase Inhibitors
◽
Chronic Phase
◽
Health Care Resource
◽
Open Label
◽
Phase 3
◽
Health Care Resource Utilization
◽
Open Label Phase
◽
Previously Treated
Download Full-text
Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial
The Lancet Oncology
◽
10.1016/s1470-2045(17)30312-1
◽
2017
◽
Vol 18
(6)
◽
pp. 732-742
◽
Cited By ~ 169
Author(s):
Véronique Diéras
◽
David Miles
◽
Sunil Verma
◽
Mark Pegram
◽
Manfred Welslau
◽
...
Keyword(s):
Breast Cancer
◽
Overall Survival
◽
Advanced Breast Cancer
◽
Descriptive Analysis
◽
Trastuzumab Emtansine
◽
Her2 Positive
◽
Open Label
◽
Phase 3
◽
Open Label Phase
◽
Previously Treated
Download Full-text
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectal cancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial
The Lancet Oncology
◽
10.1016/s1470-2045(19)30027-0
◽
2019
◽
Vol 20
(6)
◽
pp. 849-861
◽
Cited By ~ 74
Author(s):
Cathy Eng
◽
Tae Won Kim
◽
Johanna Bendell
◽
Guillem Argilés
◽
Niall C Tebbutt
◽
...
Keyword(s):
Colorectal Cancer
◽
Randomised Controlled Trial
◽
Metastatic Colorectal Cancer
◽
Controlled Trial
◽
Open Label
◽
Phase 3
◽
Open Label Phase
◽
Previously Treated
◽
Randomised Controlled
Download Full-text
Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA): final overall survival results from a randomised open-label phase 3 trial
The Lancet Oncology
◽
10.1016/s1470-2045(17)30313-3
◽
2017
◽
Vol 18
(6)
◽
pp. 743-754
◽
Cited By ~ 144
Author(s):
Ian E Krop
◽
Sung-Bae Kim
◽
Antonio Gonzalez Martin
◽
Patricia M LoRusso
◽
Jean-Marc Ferrero
◽
...
Keyword(s):
Breast Cancer
◽
Overall Survival
◽
Metastatic Breast
◽
Trastuzumab Emtansine
◽
Her2 Positive
◽
Open Label
◽
Phase 3
◽
Open Label Phase
◽
Previously Treated
◽
Versus Treatment
Download Full-text
Sign in / Sign up
Close
Export Citation Format
Close
Share Document
Close